Joseph E Wolfer, M.A. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 34612 6th Ave S, Suite 110, Federal Way, WA 98003 Phone: 253-661-2594 Fax: 253-661-2694 |
Federal Way Audiology, Llc Audiologist Medicare: Medicare Enrolled Practice Location: 34709 9th Ave S Ste B200, Federal Way, WA 98003 Phone: 253-248-6106 |
Rochelle Wong Audiologist Medicare: Medicare Enrolled Practice Location: 118 Sw 330th St Ste 303, Federal Way, WA 98023 Phone: 800-500-8243 |
Nancy K Renne, M.A. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 34612 6th Ave S, Suite 110, Federal Way, WA 98003 Phone: 253-661-2594 Fax: 253-661-2694 |
Wendy Marie Baggott, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 34509 9th Ave S Ste 202, Federal Way, WA 98003 Phone: 253-942-2270 Fax: 253-627-7880 |
Kate Eliza Nielson, M.S. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 34617 11th Place S, Suite 101, Federal Way, WA 98003 Phone: 253-838-8516 Fax: 253-838-8517 |
Virginia Davis, M.A. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 33330 8th Ave S, Federal Way, WA 98003 Phone: 253-945-4645 |
News Archive
The PIMCO Foundation, the charitable arm of the Newport Beach-based money management firm PIMCO, today announced it has awarded $549,375 in 2009 grants to 30 US charities and community organizations.
An emerging body of research suggests that Alzheimer's disease may be linked to insulin resistance, constituting a third type of diabetes. This model is based on several observations including an increased risk of developing Alzheimer's disease for diabetic patients, and reduced insulin levels in the brain tissue of Alzheimer's disease patients. Though intriguing, the existing evidence does not reveal if defective insulin signaling is causative of Alzheimer's or how insulin resistance impacts cognitive function.
A study published in the June 1st issue of the journal SLEEP finds that longer nightly duration of continuous positive airway pressure (CPAP) use can help those suffering from obstructive sleep apnea (OSA) achieve normal daytime functioning.
Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.
By injecting a hormone produced by fat and other tissues into mice, researchers report in the November Cell Metabolism that they significantly lowered blood sugar levels in normal and obese mice.
› Verified 2 days ago